Indivior (NASDAQ:INDV) Stock Price Expected to Rise, Craig Hallum Analyst Says

Indivior (NASDAQ:INDV - Get Free Report) had its price objective raised by equities research analysts at Craig Hallum from $15.00 to $22.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Craig Hallum's price target would indicate a potential upside of 52.49% from the company's current price.

A number of other analysts also recently issued reports on the company. Piper Sandler dropped their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a report on Thursday, March 6th. Wall Street Zen raised Indivior from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Indivior presently has a consensus rating of "Buy" and an average price target of $17.00.

Indivior Stock Up 3.4%

Indivior stock opened at $14.43 on Monday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -46.66 and a beta of 0.66. Indivior has a 52-week low of $7.33 and a 52-week high of $15.91. The firm's fifty day moving average is $12.24 and its 200 day moving average is $11.14.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. The business had revenue of $266.00 million for the quarter, compared to analysts' expectations of $240.13 million. Indivior had a negative net margin of 4.02% and a negative return on equity of 97.29%. On average, equities research analysts anticipate that Indivior will post 1.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Indivior

Hedge funds and other institutional investors have recently modified their holdings of the company. Kazazian Asset Management LLC acquired a new position in shares of Indivior in the fourth quarter worth about $1,706,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Indivior in the fourth quarter worth about $1,238,000. Melqart Asset Management UK Ltd boosted its position in Indivior by 675.6% during the fourth quarter. Melqart Asset Management UK Ltd now owns 104,790 shares of the company's stock worth $1,303,000 after purchasing an additional 91,280 shares during the period. Deutsche Bank AG grew its stake in Indivior by 14.2% in the 4th quarter. Deutsche Bank AG now owns 288,473 shares of the company's stock valued at $3,586,000 after buying an additional 35,953 shares during the last quarter. Finally, Claret Asset Management Corp acquired a new position in Indivior during the 4th quarter valued at $9,304,000. Institutional investors and hedge funds own 60.33% of the company's stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.